Table 1.
Factor | Category | Discovery | Validation | ||
N | % | N | % | ||
Age | Median | 67 | 64 | ||
IQR | 21.5 | 22 | |||
Sex | Female | 34 | 37.0 | 18 | 36.7 |
Male | 58 | 63.0 | 31 | 63.3 | |
Center | Tübingen | 67 | 72.8 | 42 | 85.7 |
Dresden | 17 | 18.5 | 7 | 14.3 | |
Lübeck | 8 | 8.7 | 0 | 0.0 | |
Therapy | Anti-PD-1 | 51 | 55.4 | 14 | 28.6 |
2 mg/kg once every 3 weeks Pembro | 42 | 45.7 | 8 | 16.3 | |
3 mg/kg once every 3 weeks Pembro | 3 | 3.3 | 0 | 0.0 | |
4 mg/kg once every 6 weeks Pembro | 1 | 1.1 | 0 | 0.0 | |
400 mg once every 6 weeks Pembro | 0 | 0.0 | 1 | 2,0 | |
3 mg/kg once every 2 weeks Nivo | 5 | 5.4 | 0 | 0.0 | |
240 mg once every 2 weeks Nivo | 0 | 0.0 | 1 | 2.0 | |
480 mg once every 4 weeks Nivo | 0 | 0.0 | 4 | 8.2 | |
Anti-PD-1+anti-CTLA-4 | 41 | 44.6 | 35 | 71.4 | |
1 mg/kg Ipi+3 mg/kg Nivo once every 3 weeks | 4 | 4.3 | 3 | 6.1 | |
3 mg/kg Ipi+1 mg/kg Nivo once every 3 weeks | 37 | 40.2 | 32 | 65.3 | |
Previous systemic therapies | Immunotherapy | 20 | 21.7 | 15 | 30.6 |
Targeted therapy | 22 | 23.9 | 10 | 20.4 | |
Chemotherapy | 4 | 4.3 | 4 | 8.2 | |
None | 56 | 60.9 | 26 | 53.1 | |
LDH serum level BL | Normal | 42 | 45.7 | 20 | 40.8 |
Elevated | 50 | 54.3 | 27 | 55.1 | |
Unknown | 0 | 0.0 | 2 | 4.1 |
BL, baseline; CTLA-4, cytotoxic T-lymphocyte-associated protein 4; Ipi, ipilimumab; LDH, lactate dehydrogenase; n.a., not available; Nivo, nivolumab; PD-1, programmed cell death protein 1; Pembro, pembrolizumab.